Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ABOS

Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ABOS
DateTimeSourceHeadlineSymbolCompany
16/04/202422:00GlobeNewswire Inc.Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
04/04/202423:00GlobeNewswire Inc.Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
26/03/202422:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
21/03/202423:00GlobeNewswire Inc.Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/03/202407:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
13/03/202407:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS DaysNASDAQ:ABOSAcumen Pharmaceuticals Inc
09/03/202400:50GlobeNewswire Inc.Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
22/02/202400:00GlobeNewswire Inc.Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
15/02/202400:32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABOSAcumen Pharmaceuticals Inc
02/02/202409:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
02/02/202409:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
01/02/202423:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
01/02/202423:00GlobeNewswire Inc.Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development OfficerNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202411:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202411:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202411:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202411:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202411:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202408:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
20/01/202408:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
19/01/202408:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
19/01/202408:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
19/01/202408:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/01/202400:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
09/01/202400:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/01/202408:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/01/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/01/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/01/202408:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/01/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ABOS